These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 29522724

  • 21. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y, Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [Abstract] [Full Text] [Related]

  • 22. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M, Fernández-Robredo P, Hernández M, Bezunartea J, Reiter N, Recalde S, García-Layana A.
    Biochem Pharmacol; 2016 Mar 01; 103():129-39. PubMed ID: 26793998
    [Abstract] [Full Text] [Related]

  • 23. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S, Choi H, Rho CR.
    J Ocul Pharmacol Ther; 2016 Dec 01; 32(10):671-676. PubMed ID: 27827554
    [Abstract] [Full Text] [Related]

  • 24. Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD.
    Pons M, Marin-Castaño ME.
    Invest Ophthalmol Vis Sci; 2011 Jun 01; 52(6):3842-53. PubMed ID: 21330654
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Response to anti-VEGF-A treatment of endothelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Exp Eye Res; 2016 May 01; 146():128-136. PubMed ID: 26771090
    [Abstract] [Full Text] [Related]

  • 27. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW, Zhou MW, Zhang X, Huang WB, Gao XB, Wang W, Chen S, Zhang XY, Ding XY, Jonas JB.
    Clin Exp Ophthalmol; 2015 Jul 01; 43(5):415-21. PubMed ID: 25488632
    [Abstract] [Full Text] [Related]

  • 28. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H, Sakamoto T, Shirasawa M, Yoshihara N, Otsuka H, Sonoda S, Hisatomi T, Ishibashi T.
    Retina; 2015 May 01; 35(5):1007-15. PubMed ID: 25627091
    [Abstract] [Full Text] [Related]

  • 29. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL, Lang GK, Lang GE.
    Exp Eye Res; 2014 May 01; 122():20-31. PubMed ID: 24631334
    [Abstract] [Full Text] [Related]

  • 30. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S.
    Biochem Pharmacol; 2015 Aug 01; 96(3):278-87. PubMed ID: 26056075
    [Abstract] [Full Text] [Related]

  • 31. Effects of concentration of amyloid β (Aβ) on viability of cultured retinal pigment epithelial cells.
    Masuda N, Tsujinaka H, Hirai H, Yamashita M, Ueda T, Ogata N.
    BMC Ophthalmol; 2019 Mar 08; 19(1):70. PubMed ID: 30849957
    [Abstract] [Full Text] [Related]

  • 32. Biological Modulation of Mouse RPE Cells in Response to Subthreshold Diode Micropulse Laser Treatment.
    Li Z, Song Y, Chen X, Chen Z, Ding Q.
    Cell Biochem Biophys; 2015 Nov 08; 73(2):545-552. PubMed ID: 27352351
    [Abstract] [Full Text] [Related]

  • 33. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2008 Oct 08; 49(10):4523-7. PubMed ID: 18441313
    [Abstract] [Full Text] [Related]

  • 34. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A, Parikh VS, Singh RP, Ehlers JP, Yuan A, Rachitskaya AV, Sears JE, Srivastava SK, Kaiser PK, Schachat AP, Martin DF, Modi Y.
    Br J Ophthalmol; 2017 Jul 08; 101(7):970-975. PubMed ID: 27913442
    [Abstract] [Full Text] [Related]

  • 35. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium.
    Im S, Song MH, Elangovan M, Woo KM, Park WJ.
    Sci Rep; 2024 Jun 17; 14(1):13920. PubMed ID: 38886213
    [Abstract] [Full Text] [Related]

  • 36. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhães O, Penha FM, Farah ME.
    Br J Ophthalmol; 2011 Dec 17; 95(12):1631-7. PubMed ID: 21546514
    [Abstract] [Full Text] [Related]

  • 37. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T.
    Retina; 2018 Sep 17; 38(9):1801-1808. PubMed ID: 29280940
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.